A trial looking at everolimus and pasireotide for neuroendocrine tumours of the pancreas (COOPERATE 2)

This trial looked at everolimus and a drug called pasireotide for people with a pancreatic neuroendocrine tumour (pNET) that:

• spread elsewhere in the body (advanced)

• got worse in the last 12 months (progressive)

• was well-differentiated

Well-differentiated means that the cells in the tumour looked quite similar to normal cells. So, the cancer may grow slowly and is not as likely to spread as a poorly differentiated cancer.

This trial was open for people to join in 2010 and 2011. The team published the results 2017.